Predictors of HFNC Failure in Patients With AHRF Using Echocardiography Parameters
AHRF-ECHO
Predictors of High-Flow Nasal Cannula Failure (HFNC) in Patients With Acute Hypoxemic Respiratory Failure (AHRF) Using Echocardiography Parameters
1 other identifier
observational
28
1 country
1
Brief Summary
Right ventricular dysfunction (RVD) and right ventricular-pulmonary arterial (RV-PA) uncoupling detected by transthoracic echocardiography (TTE) in acute respiratory distress syndrome (ARDS) are associated with poor survival. Early detection of RVD and RV-PA uncoupling in patients with acute hypoxemic respiratory failure (AHRF) may be indicative of worsening and decompensating pulmonary condition which may require escalation of respiratory support. The use of TTE parameters in predicting high-flow nasal cannula (HFNC) failure has not been previously studied. The objective of this study is to identify predictors of HFNC failure by TTE and to compare its performance with the well-established ROX index.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Apr 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 28, 2023
CompletedFirst Submitted
Initial submission to the registry
October 13, 2023
CompletedFirst Posted
Study publicly available on registry
October 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 26, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2024
CompletedOctober 16, 2024
October 1, 2024
1.2 years
October 13, 2023
October 15, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
High-flow nasal cannula (HFNC) therapeutic failure
Predictive value of transthoracic echocardiography (TTE) in detecting High-flow nasal cannula (HFNC) therapeutic failure in patients with acute hypoxemic respiratory failure (AHRF).
From the start of recruitment into study (i.e. start of HFNC use), till the date of study endpoint (i.e., step up to non-invasive ventilation, intubation, death on HFNC, or weaned off HFNC, whichever came first), assessed up to 4 weeks.
Interventions
Transthoracic Echocardiography to look for evidence of right ventricular (RV) dysfunction and right ventricular-pulmonary arterial (RV-PA) uncoupling.
Eligibility Criteria
Patients suffering from acute hypoxemic respiratory requiring ventilatory support with high flow nasal cannula
You may qualify if:
- Age ≧ 18; AND
- Acute hypoxemic respiratory failure (AHRF), defined by respiratory rate of greater than 25 breaths per minute and a ratio of the PaO2 to the fraction of inspired oxygen (PaO2 / FiO2) of less than 300, and use of accessory muscles of respiration or paradoxical abdominal motion; AND
- Required ventilatory support with high-flow nasal cannula (HFNC)
You may not qualify if:
- Patients suffering from hypercapnic respiratory failure; OR
- AHRF secondary to conditions that are indicated for non-invasive ventilation (NIV) (e.g. acute exacerbation of COPD, cardiogenic pulmonary edema); OR
- Use of NIV or invasive mechanical ventilation (IMV) prior to HFNC initiation; OR
- Patients with imminent need for endotracheal intubation and invasive mechanical ventilation (IMV); OR
- Patients with known or suspected diaphragm paralysis; OR
- Pregnancy; OR
- Patients with abdominal compartment syndrome; OR
- Use of HFNC for more than 12 hours prior to ICU admission; OR
- Patients with suboptimal echocardiographic image quality for data processing; OR
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Queen Mary Hospital
Hong Kong, Hong Kong
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Consultant, Adult Intensive Care Unit
Study Record Dates
First Submitted
October 13, 2023
First Posted
October 23, 2023
Study Start
April 28, 2023
Primary Completion
June 26, 2024
Study Completion
September 1, 2024
Last Updated
October 16, 2024
Record last verified: 2024-10